1. Home
  2. IGC vs TELA Comparison

IGC vs TELA Comparison

Compare IGC & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IGC Pharma Inc.

IGC

IGC Pharma Inc.

HOLD

Current Price

$0.25

Market Cap

32.0M

Sector

Health Care

ML Signal

HOLD

Logo TELA Bio Inc.

TELA

TELA Bio Inc.

HOLD

Current Price

$1.02

Market Cap

31.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IGC
TELA
Founded
2005
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.0M
31.4M
IPO Year
2005
2019

Fundamental Metrics

Financial Performance
Metric
IGC
TELA
Price
$0.25
$1.02
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $2.08
AVG Volume (30 Days)
★ 590.3K
139.6K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 59.09
37.59
EPS
★ N/A
N/A
Revenue
$1,271,000.00
★ $80,275,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$9.24
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 15.84
52 Week Low
$0.24
$0.50
52 Week High
$0.45
$1.51

Technical Indicators

Market Signals
Indicator
IGC
TELA
Relative Strength Index (RSI) 37.51 45.77
Support Level $0.24 $0.61
Resistance Level $0.30 $1.25
Average True Range (ATR) 0.01 0.12
MACD -0.00 -0.02
Stochastic Oscillator 22.55 21.77

Price Performance

Historical Comparison
IGC
TELA

About IGC IGC Pharma Inc.

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

About TELA TELA Bio Inc.

TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

Share on Social Networks: